Literature DB >> 21491489

T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease.

Stefan T Schwarz1, Timothy Rittman, Vamsi Gontu, Paul S Morgan, Nin Bajaj, Dorothee P Auer.   

Abstract

Depigmentation of the substantia nigra is a conspicuous pathological feature of Parkinson's disease and related to a loss of neuromelanin. Similar to melanin, neuromelanin has paramagnetic properties resulting in signal increase on specific T1-weighted magnetic resonance imaging. The aim of this study was to assess signal changes in the substantia nigra in patients with Parkinson's disease using an optimized neuromelanin-sensitive T1 scan. Ten patients with Parkinson's disease and 12 matched controls underwent high-resolution T1-weighted magnetic resonance imaging with magnetization transfer effect at 3T. The size and signal intensity of the substantia nigra pars compacta were determined as the number of pixels with signal intensity higher than background signal intensity+3 standard deviations and regional contrast ratio. Patients were subclassified as early stage (n=6) and late stage (n=4) using the Unified Parkinson's Disease Rating Scale and the Hoehn and Yahr Parkinson's disease staging scale. The T1 hyperintense area in the substantia nigra was substantially smaller in patients compared with controls (-60%, P<.01), and contrast was reduced (-3%, P<.05). Size reduction was even more pronounced in more advanced disease (-78%) than in early-stage disease (-47%). We present preliminary findings using a modified T1-weighted magnetic resonance imaging technique showing stage-dependent substantia nigra signal reduction in Parkinson's disease as a putative marker of neuromelanin loss. Our data suggest that reduction in the size of neuromelanin-rich substantia nigra correlates well with postmortem observations of dopaminergic neuron loss. Further validation of our results could potentially lead to development of a new biomarker of disease progression in Parkinson's disease.
Copyright © 2011 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21491489     DOI: 10.1002/mds.23722

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  57 in total

1.  Correlation between neuromelanin-sensitive MR imaging and (123)I-FP-CIT SPECT in patients with parkinsonism.

Authors:  Keita Kuya; Yuki Shinohara; Fuminori Miyoshi; Shinya Fujii; Yoshio Tanabe; Toshihide Ogawa
Journal:  Neuroradiology       Date:  2016-01-16       Impact factor: 2.804

2.  Quantitative magnetization transfer imaging of the human locus coeruleus.

Authors:  Paula Trujillo; Kalen J Petersen; Matthew J Cronin; Ya-Chen Lin; Hakmook Kang; Manus J Donahue; Seth A Smith; Daniel O Claassen
Journal:  Neuroimage       Date:  2019-06-21       Impact factor: 6.556

Review 3.  Neuromelanin of the human substantia nigra: an update.

Authors:  Fabio A Zucca; Emy Basso; Francesca A Cupaioli; Emanuele Ferrari; David Sulzer; Luigi Casella; Luigi Zecca
Journal:  Neurotox Res       Date:  2013-10-24       Impact factor: 3.911

Review 4.  Nigrosome 1 imaging: technical considerations and clinical applications.

Authors:  Eung Yeop Kim; Young Hee Sung; Jongho Lee
Journal:  Br J Radiol       Date:  2019-06-05       Impact factor: 3.039

5.  In vivo detection of lateral-ventral tier nigral degeneration in Parkinson's disease.

Authors:  Daniel E Huddleston; Jason Langley; Jan Sedlacik; Kai Boelmans; Stewart A Factor; Xiaoping P Hu
Journal:  Hum Brain Mapp       Date:  2017-02-27       Impact factor: 5.038

6.  Reproducibility of locus coeruleus and substantia nigra imaging with neuromelanin sensitive MRI.

Authors:  Jason Langley; Daniel E Huddleston; Christine J Liu; Xiaoping Hu
Journal:  MAGMA       Date:  2016-09-29       Impact factor: 2.310

Review 7.  Iron metabolism and its detection through MRI in parkinsonian disorders: a systematic review.

Authors:  Sara Pietracupa; Antonio Martin-Bastida; Paola Piccini
Journal:  Neurol Sci       Date:  2017-09-02       Impact factor: 3.307

8.  Relationship between neuromelanin and dopamine terminals within the Parkinson's nigrostriatal system.

Authors:  Antonio Martín-Bastida; Nicholas P Lao-Kaim; Andreas Antonios Roussakis; Graham E Searle; Yue Xing; Roger N Gunn; Stefan T Schwarz; Roger A Barker; Dorothee P Auer; Paola Piccini
Journal:  Brain       Date:  2019-07-01       Impact factor: 13.501

9.  Correlation between pathology and neuromelanin MR imaging in Parkinson's disease and dementia with Lewy bodies.

Authors:  Shinichiro Kitao; Eiji Matsusue; Shinya Fujii; Fuminori Miyoshi; Toshio Kaminou; Shinsuke Kato; Hisao Ito; Toshihide Ogawa
Journal:  Neuroradiology       Date:  2013-05-15       Impact factor: 2.804

Review 10.  Distinguishing Neuroimaging Features in Patients Presenting with Visual Hallucinations.

Authors:  T T Winton-Brown; A Ting; R Mocellin; M Walterfang; D Velakoulis; F Gaillard
Journal:  AJNR Am J Neuroradiol       Date:  2016-01-07       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.